Im SA, Mukai H, Park IH, et al. - Given a significantly improved progression-free survival (PFS) was reported in PALOMA-2 wherein palbociclib plus letrozole was adopted as initial therapy for estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer, researchers investigated the advantages of palbociclib plus letrozole in Asian postmenopausal women (n = 95). In a random manner 2:1, palbociclib plus letrozole or placebo plus letrozole was administered to patients. Consistent with the overall study population, a significantly improved PFS was reported in Asians in relation to treatment with palbociclib plus letrozole. More frequent hematologic toxicities were reported in Asians vs non-Asians but these toxicities were manageable with early dose changes while maintaining quality of life.